mRNA Cancer Vaccine Succeeds in Late-Stage Trial, Companies Say

A cancer vaccine utilizing messenger ribonucleic acid (mRNA) technology prevented skin cancer from recurring in a phase 3 clinical trial, companies that make the vaccine said on Aug. 19.

The trial participants were people who underwent surgery to remove skin cancer.

The vaccine also prevented cancer from spreading in the patients, Moderna and Merck said.